RFS Pharma LLC
6Patents
5Active
6Granted
45Portfolio score
Filing activity: Jul 22, 2004 → Oct 28, 2011 · 3 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8609627B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | Emerging Cross-Sectional Technologies | 71 | Active |
| US8895531B2 | 2′-fluoronucleoside phosphonates as antiviral agents | Chemistry; Metallurgy | 22 | Active |
| US8815829B2 | 3′-azido purine nucleotide prodrugs for treatment of viral infections | Chemistry; Metallurgy | 22 | Active |
| US8859595B2 | Potent and selective inhibitors of hepatitis C virus | Chemistry; Metallurgy | 22 | Active |
| US7560550B2 | Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives | Chemistry; Metallurgy | 21 | Expired |
| US8729014B2 | Specific HCV NS3 protease inhibitors | Human Necessities | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.